InMed is a biopharmaceutical company that specializes in the discovery and development of novel, cannabinoid-based therapeutics for the treatment of diseases with high unmet medical need.
InMed employs a highly scientific approach to designing and developing medicines, which will help unlock the full potential of cannabinoid pharmaceuticals. One proprietary technology is our bioinformatics platform, which uses a computer-based drug candidate selection process to reach high-probability conclusions from massive, publicly available databases together with an internal library of cannabinoid drug information.
InMed is also developing a robust, high-yield, microbial-based biosynthesis process designed to enable the manufacturing of the multitude of cannabinoids (90+) found from natural sources. InMed’s products are designed to be bio-identical to the naturally-occurring cannabinoids and the process envisioned to offer cost and time savings, and superior ease, control and quality of manufacturing when compared to alternative methods.